Twist Bioscience Corp
For the period ended Sep 30, 2025. Filed Nov 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Nov 17, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year ended September 30, | |||
|---|---|---|---|
| (In thousands, except per share data) | 2025 | 2024 | 2023 |
| Revenues [1] | $376,572 | $312,974 | $245,109 |
| Costs and expenses: | |||
| Cost of revenues | $185,570 | $179,625 | $155,380 |
| Research and development expenses | 80,285 | 90,852 | 106,894 |
| Selling, general and administrative expenses | 246,976 | 218,398 | 189,738 |
| Restructuring and other costs | — | — | 9,384 |
| Change in fair value of contingent considerations and holdbacks | — | — | (5,913) |
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
| Gain on sale of business | 48,847 | — | — |
| Interest income | 11,364 | 15,344 | 14,365 |
| Other income (expense), net [2] | (903) | (2,679) | (672) |
| Loss before income taxes | $(76,951) | $(208,166) | $(203,466) |
| Income tax expense | (719) | (560) | (1,152) |
| Net loss attributable to common stockholders | $(77,670) | $(208,726) | $(204,618) |
| Other comprehensive income (loss): | |||
| Change in unrealized gain (loss) on investments | $(50) | $203 | $1,510 |
| Foreign currency translation adjustment | (55) | 31 | (423) |
| Comprehensive loss | $(77,775) | $(208,492) | $(203,531) |
| Net loss per share attributable to common stockholders—basic and diluted | $(1.30) | $(3.60) | $(3.60) |
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 59,808 | 58,016 | 56,885 |
[1]Including revenues from related parties of $12.2 million, $12.1 million and $5.9 million during the year end September 30, 2025, 2024 and 2023, respectively.
[2]Including sublease income from a related party of $1.1 million, $— million and $— million during the year end September 30, 2025, 2024 and 2023, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.